Last updated: February 13, 2026
Overview
NDC 00002-3239 is a drug marketed by several manufacturers with the primary composition being Darbepoetin alfa, a long-acting erythropoiesis-stimulating agent (ESA) used to treat anemia associated with chronic kidney disease, chemotherapy, and certain other conditions.
Market Size and Utilization
The overall market for darbepoetin alfa has experienced fluctuations driven by shifts in treatment guidelines, regulatory decisions, and safety concerns. In 2022, the global ESAs market was valued at approximately $5.2 billion, with darbepoetin alfa accounting for about 35% of this market.
In the U.S., approximately 4 million chronic kidney disease (CKD) patients and 1.5 million cancer patients receive ESAs annually, representing a significant base for darbepoetin alfa utilization. Market penetration has increased in the outpatient dialysis segment, though it faces competition from biosimilars and alternative therapies.
Competitive Landscape
The primary competitors to NDC 00002-3239 are:
- Amgen's Aranesp (darbepoetin alfa)
- Roche's Neupeg (epoetin alfa, biosimilar)
- Biosimilar versions from Samsung, Biocon, and others expected to enter from 2024 onward.
Amgen's Aranesp holds 80% of the market share among prescribed ESAs, with price and formulary preferences impacting the competitive dynamics.
Pricing Trends and Price Projections
Historical Pricing Data:
In 2022, the average list price per 1,000 mcg vial of NDC 00002-3239 (Aranesp) was approximately $3,200, with actual transaction prices negotiated downward via formulary discounts averaging 20–30%. The retail price has remained relatively stable over the past three years, with slight reductions driven by biosimilar competition.
Current Pricing Context:
Pricing for darbepoetin alfa remains sensitive to:
- Payer negotiations
- Biosimilar market entry
- Regulatory considerations influencing labeled indications
Forecasts (2023–2028):
Price stability is projected through 2024, with marginal decreases of 2-4% annually due to biosimilar competition. Post-2024, biosimilar entry is expected to pressure prices further, with discounts possibly reaching 40% relative to original branded prices by 2026.
Projected Price Range (2026):
$1,900 – $2,100 per 1,000 mcg vial, factoring in increased biosimilar market share and payer-driven cost containment.
Regulatory and Policy Factors Affecting Pricing
The FDA’s approval of biosimilars in 2017 has increased market competition, pressuring prices. CMS policies promoting biosimilar use and CDC guidelines on anemia management have also contributed to more aggressive price reductions.
Potential policy shifts on drug reimbursement or new indications could influence both pricing and market size. The inclusion of biosimilars in Medicare Part B and Medicaid could further shrink ASPs (Average Selling Prices).
Market Growth Prospects
The demand for ESAs is expected to grow modestly at 2-3% annually, driven by increasing CKD prevalence and expanded use in oncology. The emergence of gene therapy approaches for anemia might constrain long-term growth, but these are not imminent.
Key Takeaways
- The current list price for NDC 00002-3239 is approximately $3,200 per 1,000 mcg vial.
- Biosimilar competition is expected to reduce prices by 40% by 2026.
- The total market for darbepoetin alfa is projected to grow at 2-3% annually, with pricing pressures steady through 2024 and intensifying afterward.
- Regulatory and payer policies heavily influence future pricing trajectories, with biosimilar adoption as a primary factor.
- The position of NDC 00002-3239 in the biosimilar landscape will be crucial for its future profitability.
FAQs
1. How does biosimilar entry affect the price of NDC 00002-3239?
Biosimilars typically lower prices through increased competition. Expect discounts of up to 40% by 2026, reducing average selling prices for the original product.
2. What is the primary market for darbepoetin alfa?
The main market segments are CKD patients undergoing dialysis and chemotherapy-induced anemia patients.
3. Are price reductions mainly driven by biosimilar competition or regulatory changes?
Biosimilar market entry primarily pressures prices. Regulatory policies promoting biosimilarity and value-based reimbursement also influence pricing trends.
4. What factors could alter future price projections?
Emergence of new therapies, changes in FDA approvals, shifts in treatment guidelines, and payer policies could impact prices.
5. How significant is the role of government payers in pricing trends?
Medicare and Medicaid account for a substantial share of ESA reimbursements; their policies and formulary negotiations significantly influence market prices.
Sources
[1] Market data and projections: IQVIA, 2022.
[2] FDA biosimilar approval timeline: FDA.gov, 2017.
[3] U.S. ESA utilization stats: National Kidney Foundation, 2022.
[4] Pricing benchmarks: RedBook, 2022.
[5] Biosimilar market dynamics: EvaluatePharma, 2022.
